Q3 2025 Earnings Call Transcript November 7, 2025 Operator: Good day, and welcome to the Cidara Therapeutics Q3 2025 ...

A new delivery particle developed at MIT could make mRNA vaccines more effective and potentially lower the cost per vaccine ...

The team used the AMG1541 LNP to deliver an mRNA influenza vaccine in mice. They compared this vaccine’s effectiveness to a flu vaccine made with the lipid SM-102, which is FDA-approved and was used ...

A new lipid nanoparticle could make mRNA vaccines more effective and potentially lower the cost per dose. New research suggests an mRNA influenza vaccine delivered with the new particle could generate ...

Following restricted vaccine approvals and changes to CDC immunization schedules, Merck, Pfizer, GSK and Sanofi are all suffering revenue hits to their vaccine programs.

Savvy Living: What Seniors Need to Know About This Fall’s Vaccines – The Centers for Disease Control and Prevention (CDC) the overall fall vaccine recommendations for “older adults” resembles last ...

Q3 2025 Earnings Call Transcript November 6, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-0.51282, expectations were $-2.15. Operator: Good day, and thank you for standing by.

There are few more divisive issues in medicine today than the topic of vaccines. Until COVID, most Americans were glad to have their children vaccinated against measles, mumps, rubella, polio, HepB, ...

Announced expanded and accelerated Phase 3 Plan for CD388, its non-vaccine influenza preventative therapeutic Enrolled and dosed first patients ...

Moderna posts a smaller Q3 loss, trims 2025 sales forecast, cuts R&D costs, and boosts cash outlook as COVID vaccine demand ...